Under 10% of patients that would benefit from obesity jabs like Wegovy can access them, states the WHO as it issues its inaugural guidance on the drugs.
With over a billion people worldwide currently living with obesity, it is urging broader and more equitable availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The latest guidelines affirms that excess weight is a chronic disease that can be managed with comprehensive and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to broad availability to the jabs that can aid individuals in losing substantial body mass, says the agency.
Skinny Jab Shortage
Even in the present best projected case, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation calls on governments and firms to increase access, by approaches such as patent sharing.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Work
The injections imitate a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so individuals consume fewer calories.
Individuals usually begin shedding pounds within a few weeks of beginning the weekly injections.
Studies points to patients may regain a significant portion after a year of stopping the medication, as their usual appetite return.
To be carrying excess weight elevates your risk for developing diseases, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the health agency.
